Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMareike VerbeekCSChristof ScheidKNKathrin Nachtkamp

Discussion

Loading...

Member takes

Overview

Phase I/II trial combined venetoclax and Treosulfan in patients with high-risk myeloid malignancies, highlighting safe outcomes and early benefits.

Key Points

  • All patients achieved neutrophil recovery by day 14 after treatment with treosulfan and venetoclax.
  • Adverse events included hematotoxicity and gastrointestinal disorders, typical post-transplant complications.
  • Phase I/II trial used a classical 3+3 design to escalate venetoclax doses effectively.
  • Prospective findings indicate safety of combining venetoclax with treosulfan for high-risk patients, paving way for larger trials.

Cite This Study

Verbeek et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba2https://doi.org/10.1182/blood-2025-5992
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)2025
  2. 2The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients2025
  3. 3Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  4. 4Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation2025
  5. 5Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations